IT IS devastating to hear that Kadcyla, a crucial life-extending treatment for women with incurable secondary breast cancer, faces being withdrawn from the NHS, following the failure of NICE and the drug’s manufacturer, Roche, to reach an agreement. Kadcyla can offer patients precious extra months, even years, of good quality time with their loved ones, with fewer side effects than other treatments.